Bradley Everly, MD
Family Medicine · Maumee, OHNPI 1053561993
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $263,660 of the $266,158 with a category attached, or 99.1%. 31 manufacturers reported payments, led by CSL Plasma Inc. at 58.9% of the total. Among family medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $562.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$157K
- CSL Behring$107K
- AbbVie$388
- Novo Nordisk$264
- AstraZeneca$237
- Pfizer$219
- plus $1K from 25 others
What the payments were for
- Consulting fees$263,66099%
- Food & beverage$2,4571%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 160 | $156,704 |
| CSL Behring | 129 | $106,955 |
| AbbVie(2 entities) | 29 | $388 |
| Novo Nordisk | 20 | $264 |
| AstraZeneca | 8 | $237 |
| Pfizer | 27 | $219 |
| GSK | 15 | $157 |
| Boehringer Ingelheim | 9 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $118 |
| Merck | 7 | $92 |
| Amgen | 6 | $88 |
| Amarin Pharma, Inc. | 6 | $85 |
| Lilly USA, LLC | 5 | $79 |
| Kowa Pharmaceuticals America, Inc. | 5 | $74 |
| Novartis | 5 | $73 |
| Johnson & Johnson | 5 | $70 |
| Eisai Inc. | 4 | $59 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $47 |
| Jazz Pharmaceuticals Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Almatica Pharma LLC | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Mannkind Corporation | 2 | $24 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
How this compares
$266,158 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $126,605 |
| EliquisApixaban | 128 | $119,915 |
| MounjaroTirzepatide | 37 | $62,430 |
| TrulicityDulaglutide | 31 | $47,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $45,885 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $45,291 |
| JardianceEmpagliflozin | 31 | $42,055 |
| VraylarCariprazine Hcl | 17 | $30,566 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $26,353 |
| LinzessLinaclotide | 29 | $24,792 |
| XareltoRivaroxaban | 16 | $24,261 |
| JanuviaSitagliptin Phosphate | 23 | $24,124 |
| FarxigaDapagliflozin Propanediol | 24 | $23,704 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $20,710 |
| Buprenorphine | 55 | $17,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $219 | $132,977141 claims |
| Novo NordiskOzempic | $264 | $126,60585 claims |
| Lilly USA, LLCMounjaro, Trulicity | $79 | $109,79168 claims |
| MerckJanumet, Januvia, Janumet Xr | $92 | $71,18670 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $157 | $57,86366 claims |
| AbbVieVraylar, Linzess | $388 | $55,35846 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $152 | $51,32045 claims |
| Johnson & JohnsonXarelto | $70 | $24,26116 claims |
| AstraZenecaFarxiga | $237 | $23,70424 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl | $16 | $19,337109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Maumee
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
- Paul HanahanPainesville$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.